Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Soltysiak

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Cellular and Molecular Neurobiology|June 27, 2003
P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosisSeong G Kim, Zhan-Guo Gao, Kelly A Soltysiak, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Synthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose ringsG Ravi, K Lee, X Ji, et al.
Medicine|January 5, 2019
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case reportSebastian Burgos, Guillermo Montalban-Bravo, Lucia Fuente, et al.
Leukemia & Lymphoma|February 11, 2020
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agentsKelly S Chien, Caleb A Class, Guillermo Montalban-Bravo, et al.
Cancer|November 20, 2019
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaKoji Sasaki, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Leukemia Research|September 25, 2018
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Juliana E Hidalgo-Lopez, Srdan Verstovsek, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Leukemia|November 14, 2019
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromesGuillermo Montalban-Bravo, Caleb A Class, Irene Ganan-Gomez, et al.
Leukemia|June 13, 2022
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemiaYue Wei, Rashmi Kanagal-Shamanna, Hong Zheng, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Cellular and Molecular Neurobiology|June 27, 2003
P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosisSeong G Kim, Zhan-Guo Gao, Kelly A Soltysiak, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Synthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose ringsG Ravi, K Lee, X Ji, et al.
Medicine|January 5, 2019
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case reportSebastian Burgos, Guillermo Montalban-Bravo, Lucia Fuente, et al.
Leukemia & Lymphoma|February 11, 2020
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agentsKelly S Chien, Caleb A Class, Guillermo Montalban-Bravo, et al.
Cancer|November 20, 2019
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaKoji Sasaki, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Leukemia Research|September 25, 2018
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activationYasmin Abaza, Juliana E Hidalgo-Lopez, Srdan Verstovsek, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Leukemia|November 14, 2019
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromesGuillermo Montalban-Bravo, Caleb A Class, Irene Ganan-Gomez, et al.
Leukemia|June 13, 2022
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemiaYue Wei, Rashmi Kanagal-Shamanna, Hong Zheng, et al.
Pageof 5